Targeting the Insulin-Like Growth Factor-1 Receptor (IGF-1R), a protein involved in the pathogenesis of bone and soft tissue sarcomas, is another strategy explored in osteosarcoma trials. This evidence concerns the gene IGF1R and osteosarcoma.